Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2006 1
2008 2
2009 3
2010 3
2011 3
2012 3
2013 2
2014 3
2015 3
2016 3
2017 2
2018 2
2019 3
2020 3
2021 5
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
Rossi A, Orecchioni S, Falvo P, Tabanelli V, Baiardi E, Agostinelli C, Melle F, Motta G, Calleri A, Fiori S, Corsini C, Casadei B, Mazzara S, Vitolo U, Bertolini F, Zinzani PL, Alcalay M, Pelicci PG, Pileri S, Tarella C, Derenzini E. Rossi A, et al. Among authors: calleri a. Leukemia. 2022 Jan;36(1):197-209. doi: 10.1038/s41375-021-01347-6. Epub 2021 Jul 24. Leukemia. 2022. PMID: 34304248 Free PMC article. Clinical Trial.
Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects.
Sapienza MR, Pileri A, Derenzini E, Melle F, Motta G, Fiori S, Calleri A, Pimpinelli N, Tabanelli V, Pileri S. Sapienza MR, et al. Among authors: calleri a. Cancers (Basel). 2019 Apr 28;11(5):595. doi: 10.3390/cancers11050595. Cancers (Basel). 2019. PMID: 31035408 Free PMC article. Review.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M. Leupin N, et al. Among authors: calleri a. Cancer. 2022 Mar 1;128(5):1004-1014. doi: 10.1002/cncr.34005. Epub 2021 Nov 2. Cancer. 2022. PMID: 34726773 Free article. Clinical Trial.
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
Derenzini E, Tabanelli V, Sammassimo S, Mazzara S, Motta G, Melle F, Vanazzi A, Calleri A, Fiori S, Finazzi MC, Barbanti MC, Ramadan S, Gandini S, Pastano R, Rambaldi A, Pileri S, Tarella C. Derenzini E, et al. Among authors: calleri a. Bone Marrow Transplant. 2021 Sep;56(9):2280-2283. doi: 10.1038/s41409-021-01320-y. Epub 2021 May 7. Bone Marrow Transplant. 2021. PMID: 33963303 No abstract available.
Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes.
Cella CA, Spada F, Berruti A, Bertolini F, Mancuso P, Barberis M, Pisa E, Rubino M, Gervaso L, Laffi A, Pellicori S, Radice D, Zorzino L, Calleri A, Funicelli L, Petralia G, Fazio N. Cella CA, et al. Among authors: calleri a. Cancers (Basel). 2022 Sep 15;14(18):4471. doi: 10.3390/cancers14184471. Cancers (Basel). 2022. PMID: 36139632 Free PMC article.
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. Tabanelli V, et al. Among authors: calleri a. Blood Adv. 2022 Aug 9;6(15):4634-4644. doi: 10.1182/bloodadvances.2022007046. Blood Adv. 2022. PMID: 35767735 Free PMC article.
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.
Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S. Derenzini E, et al. Among authors: calleri a. Haematologica. 2021 Sep 1;106(9):2405-2416. doi: 10.3324/haematol.2019.236455. Haematologica. 2021. PMID: 32817282 Free PMC article.
42 results